Stockscreener 앱 받기
3.18
0.31%
-0.010
시간 외 거래:
3.25
0.07
+2.20%
Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스
Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Pasithea Therapeutics Announces Positive Safety Review - GlobeNewswire
Pasithea's PAS-004 Drug Shows Strong Safety Profile in Phase 1 Trial, Zero Toxicity Issues | KTTA Stock News - StockTitan
Pasithea Therapeutics (NASDAQ:KTTA) Shares Up 2.4% – Still a Buy? - Defense World
KTTA stock touches 52-week low at $3.19 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $3.19 amid market challenges - Investing.com UK
ARMISTICE CAPITAL, LLC Acquires New Stake in Pasithea Therapeuti - GuruFocus.com
KTTA stock touches 52-week low at $3.4 amid market challenges - Investing.com Australia
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA) - The Wall Street Transcript
KTTA stock touches 52-week low at $3.6 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $3.6 amid market challenges By Investing.com - Investing.com South Africa
pasithea therapeutics corp Earnings dates - RTTNews
(KTTA) Investment Analysis - Stock Traders Daily
Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Act - GuruFocus.com
Was there any good news for Pasithea Therapeutics Corp (KTTA) stock in the last session? - US Post News
Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com
Market cap of Pasithea Therapeutics Corp [KTTA] reaches 6.08M – now what? - The DBT News
PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors - OncLive
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Stock Gains After Private Placement - DRP Journal
Pasithea Therapeutics drops 19% on $5M private placement - MSN
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Grid Battery Metals Inc. (TSXV:CELL) (OTCQB:EVKRF) Stock Gains Momentum: Is It Sustainable? - DRP Journal
Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share - TipRanks
Technical Explosions: DUO, KTTA, TBIO, GOTUWatch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum! - openPR
Schwab Splitting Shares for Two-Thirds of ETF Lineup - Yahoo! Voices
Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials - Investorideas.com newswire
Dow Surges Over 250 Points; Accenture Earnings Top Views - Benzinga
Stocks Stay Higher With Tech Still Driving Gains: Markets Wrap - Yahoo Finance
Why XPeng Stock Spiked Higher Today - Yahoo! Voices
Why Is Pasithea Therapeutics Stock Surging On Thursday? - AOL
KTTA’s price-to-free cash flow ratio: What it means for investors - US Post News
Crude Oil Down Over 2%; US Initial Jobless Claims Fall - Benzinga
English cricket ‘disconnected from reality’ in valuation of the Hundred - Yahoo! Voices
Pasithea Therapeutics Shares Move Higher After Positive Data for Cancer Treatment - MarketWatch
Pasithea reports positive early data on cancer drug PAS-004 - Investing.com India
Visa agrees to buy AI-focused enterprise tech firm Featurespace - Yahoo! Voices
Pasithea Therapeutics (KTTA) Sees Strong Pre-Market Gains - Stocks Telegraph
Pasithea Therapeutics rises on positive early-stage data from cancer drug - XM
Pasithea Therapeutics : Investor Presentation - Marketscreener.com
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), And Preliminary Efficacy Data From Its Phase 1 Clinical T... - MENAFN.COM
Pasithea Therapeutics announces initial data from Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics (KTTA) Reports Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from Phase 1 Trial of PAS-004 - StreetInsider.com
Pasithea Therapeutics Announces Positive Initial Safety, - GlobeNewswire
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - StockTitan
Factbox-OpenAI key personnel changes - Yahoo! Voices
Why Viking Therapeutics Stock Was So Healthy on Wednesday - Yahoo Finance
Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding - Marketscreener.com
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Capstan Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC - OncLive
The OncFive: Top Oncology Articles for the Week of 9/15 - OncLive
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate - Yahoo Finance
Are Robust Financials Driving The Recent Rally In TG Therapeutics, Inc.'s (NASDAQ:TGTX) Stock? - Yahoo Finance
Pasithea Therapeutics (NASDAQ:KTTA) Trading Up 25.8% - Defense World
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Yahoo Finance
KTTAPasithea Therapeutics Corp. Latest Stock News & Market Updates - StockTitan
Saghmos Therapeutics Announces Presentation at UBS 2024 Biotechnology Private Company Virtual Symposium - Yahoo Finance
0.93%
3.55%
자본화:
|
볼륨(24시간):